title: Oral weekly ibandronate prevents bone loss in postmenopausal women.
abstract: OBJECTIVE
  To investigate the efficacy, safety, and dose-response of once-weekly oral ibandronate in the prevention of postmenopausal bone loss.
  
  
  METHODS
  This was a multi-centre, placebo-controlled, double-blind, randomized, 24-month phase II/III dose-finding study.
  
  
  METHODS
  Primary care units in 14 osteoporosis centres.
  
  
  METHODS
  A total of 630 women were stratified into four strata according to time since menopause (TSM, 1-3 vs. >3 years) and baseline bone mineral density (BMD; normal: T-score > or =1 vs. osteopenic: -2.5 < or = T-score < or = 1) of the lumbar spine.
  
  
  METHODS
  Within each stratum women were further randomized to receive once-weekly ibandronate (5, 10, or 20 mg week-1) or placebo for 24 months.
  
  
  METHODS
  Efficacy parameters were the relative changes from baseline in spine (L1-4) and hip BMD, and biochemical markers of bone turnover (serum and urinary C-telopeptide of collagen type I (CTx), osteocalcin, and alkaline phosphatase) measured by dual energy X-ray absorptiometry and enzyme immunoassays, respectively.
  
  
  RESULTS
  Once-weekly therapy with ibandronate induced dose-dependent increases in spine and hip BMD. At month 24, differences between the relative changes in spine and hip BMD induced by 20 mg ibandronate and placebo was 4.0 and 2.7%, respectively. Similar or more pronounced differences were seen in osteopenic women of TSM 1-3 years (5.3 and 3.5%) and of TSM >3 years (3.5 and 2.9%), respectively. A dose-dependent suppression of all biochemical markers of bone turnover was observed with significant decreases in the 20 mg dose groups of all strata at month 24. The overall safety results indicated that once-weekly oral ibandronate was well-tolerated at all three doses.
  
  
  CONCLUSIONS
  Once-weekly oral therapy with 20 mg ibandronate provides an effective and safe therapy for the prevention of postmenopausal bone loss.
authors.affiliation: Center for Clinical and Basic Research A/S, Ballerup and Vejle, Denmark.
authors.forename: L B
authors.initials: LB
authors.lastname: Tankó
authors.forename: D
authors.initials: D
authors.lastname: Felsenberg
authors.forename: E
authors.initials: E
authors.lastname: Czerwiński
authors.forename: A
authors.initials: A
authors.lastname: Burdeska
authors.forename: I
authors.initials: I
authors.lastname: Jonkanski
authors.forename: C
authors.initials: C
authors.lastname: Hughes
authors.forename: C
authors.initials: C
authors.lastname: Christiansen
mesh_terms: D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D001862:Bone Resorption / Q000188:drug therapy / Q000503:physiopathology; D024042:Collagen Type I / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D024042:Collagen Type I; D004164:Diphosphonates; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D000077557:Ibandronic Acid